James Tasch, DO
Pulmonary Disease · Brighton, MANPI 1689031742
Payments from drug & device makers
Across 83 payments — averaging $35.59 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$1K
- GSK$266
- Regeneron Healthcare Solutions, Inc.$193
- Medtronic$149
- Actelion Pharmaceuticals US, Inc.$122
- Amgen$109
- plus $919 from 20 others
What the payments were for
- Food & beverage$2,86597%
- Education$893%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 26 | $1,196 |
| GSK | 12 | $266 |
| Regeneron Healthcare Solutions, Inc. | 7 | $193 |
| Medtronic | 1 | $149 |
| Actelion Pharmaceuticals US, Inc. | 1 | $122 |
| Amgen | 4 | $109 |
| Sanofi | 5 | $109 |
| Exelixis Inc. | 2 | $84 |
| Sanofi-aventis U.S. LLC | 1 | $75 |
| Boehringer Ingelheim | 2 | $61 |
| Seagen Inc. | 2 | $60 |
| Merck | 2 | $56 |
| AbbVie | 2 | $55 |
| Verona Pharma, Inc. | 2 | $54 |
| Eisai Inc. | 2 | $50 |
| Mirati Therapeutics, Inc. | 1 | $40 |
| Bayer | 1 | $35 |
| Resmed Corp | 2 | $34 |
| Lilly USA, LLC | 1 | $31 |
| Pharmacyclics LLC, An Abbvie Company | 1 | $30 |
| Beigene USA, Inc. | 1 | $29 |
| E.r. Squibb & Sons, L.L.C. | 1 | $26 |
| Sobi, Inc | 1 | $25 |
| CTI Biopharma Corp. | 1 | $25 |
| Gilead | 1 | $25 |
| ZOLL Respicardia, Inc. | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$2,954 in reported general payments places this provider in the 70th percentile of 482 pulmonary disease providers in Massachusetts.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OfevNintedanib Esylate | 36 | $468,713 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 232 | $182,670 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 95 | $53,226 |
| Spiriva RespimatTiotropium Bromide | 68 | $41,667 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 44 | $31,117 |
| Incruse ElliptaUmeclidinium Bromide | 70 | $24,051 |
| Breo ElliptaFluticasone/Vilanterol | 41 | $19,287 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 17 | $14,162 |
| Arnuity ElliptaFluticasone Furoate | 35 | $8,803 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 326 | $8,761 |
| Qvar RedihalerBeclomethasone Dipropionate | 30 | $8,368 |
| DuleraMometasone/Formoterol | 17 | $7,166 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 30 | $5,930 |
| Fluticasone Propionate HfaFluticasone Propionate | 19 | $3,665 |
| Wixela InhubFluticasone Propion/Salmeterol | 16 | $2,564 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimOfev, Spiriva Respimat, Stiolto Respimat | $61 | $524,541121 claims |
| GSKTrelegy Ellipta, Anoro Ellipta, Incruse Ellipta, Breo Ellipta, Arnuity Ellipta | $266 | $288,036473 claims |
| AstraZenecaBreztri Aerosphere | $1,196 | $31,11744 claims |
| MerckDulera | $56 | $7,16617 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 482 pulmonary disease providers in Massachusetts.
Other pulmonary disease in Brighton
- Aaron WaxmanBoston$7.7M
- John BerkBoston$6M
- Darrell KottonBoston$5.3M
- Hilary GoldbergBoston$3.5M
- Ehab BillatosWinchester$2.7M
- Harrison FarberBoston$2.6M
- Elizabeth KlingsBoston$2.1M
- Curtis MelloNorth Dartmouth$1.9M
- Gary HunninghakeBoston$1.5M
- Elliot IsraelBrookline$1.4M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.